Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 249
Tipo Título / Nombre Autor(es) Año
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). P Ribera JM, Morgades M, Ciudad J, Barba P, Martino R, Montesinos P, Vives S, Moreno MJ, Soria B, Cil C, González Campos J, Amigo ML, Novo A, Torno M, Bermudéz A, Serrano A, Bernal T, López A, Bergua J, Escoda L, Martínez P, Alonso N, Mercadas S, Abella E, Cuardia R, Vall-llovera F, Cladera A, Esteve J, García Boyero R, Feliu E, Orfao A 2015
Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain Pineda A, Sancho JM, García O, Esteve J, Tormo M, Martínez P, Vall-llovera F, Martino R, Montesinos P, González Campos J, Bergua J, Calbacho M, Gil C, Vicent A, Cladera A, Hernández J, Moreno MJ, Serrano A, Alonso N, García R, Barba P, Fernández A, Miralles P, Novo A, Moraleda JM, Hernández JA, Abella E, Sánchez M, López ME, Bernal T, Mateos MC, Lavilla E, Ribera JM 2015
Relationship between Antiphospholipid Syndrome clinical manifestations and multiple positive antiphospholipid antibodies. Sigüenza R, Bermejo N, Casas I, Ibañez F, Bañas MH, Bergua JM, Arcos MJ, Prieto J, Martin-Mateos ML, Cabrera C, Perez-Leal FA 2015
CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplactics Syndromes (MDS) Sigüenza R, Bañas MH, Casas I, Ibañez F, Bermejo N, Bergua JM, Arcos MJ, Prieto J, Martin-Mateos ML, Cabrera C, Perez-Leal FA 2015
Long-term anticoagulation with dabigatran in patients with severe lactose intolerance Bermejo N, Sigúenza R, Ibañez F, Bañas MH, Casas I, Pérez-Leal FA, Bergua J 2015
Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score Falantes JF, Martinez Robles V, Bargay J, Deben G, Garrido A, Casano J, Salamero O, Bergua JM, Colado E, Garcia R, Pedro C, Redondo S, Tormo M, Bonanad S, Diez-Campelo M, Perez-Encinas M, de la Fuente A, Xicoy B, Montesinos P, 2015
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group Purroy N, Bergua J, Gallur L, Prieto J, López LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, López A 2015
Dos pacientes mujeres, jóvenes, con fiebre y un mismo destino Sigüenza Salgado R, Ibáñez Espacio F, Casas Avilés I, Flores Guerrero A, Bañas Llanos H, Martín Aguilera C, Bermejo Vega N, Arcos Carmona MJ, Martín Mateos M, Prieto Fernández J, Cabrera Silva C, Carnicero F, Bergua Burgués J 2014
Azacitidine in older patients with acute Myeloid leukemia (AML) and adverse karyotype. Subanalisis from the Alma Study Falantes J, Deben G, Martinez Robles V, Bargay J, Salamero O, Pedro C, Redondo S, Garrido A, Bergua JM, Tormo M, Xicoy B, Font P, González-López TJ, Ramos F 2014
Novel assay for ex vivo evaluation of antiproliferative effect of hypomethylating agents 5-Azacytidine and Decitabine in AML patient samples Hernández P, Montesinos P, Serrano J, Herrera P, Bergua J, Colorado M, González BJ, Gómez C, Robles A, Gorrochategui J, Sánchez J, Ballesteros J, Moscardo F, Martínez D, Sanz MA, Pérez de Oteyza J, Martínez J 2014